Science
FDA Approves Zanidatamab-Based Combination for HER2-Positive Gastroesophageal Cancers – The Babak Lab HK
The Babak Lab HK

FDA Approves Zanidatamab-Based Combination for HER2-Positive Gastroesophageal Cancers – The Babak Lab HK

The Babak Lab HK shared on X:

“The FDA has approved zanidatamab-hrii (Ziihera) in combination with tislelizumab-jsgr and chemotherapy for adults with HER2-positive, unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.”

Learn more about the approval

You might be interested in:

Phase 1b/2 HERBOT Trial: First-Line HER2-Targeted Chemoimmunotherapy in Biliary Tract Cancer

OncoDaily

cancer esophageal adenocarcinoma FDA gastric adenocarcinoma Gastroesophageal Junction Adenocarcinoma OncoDaily Oncology The Babak Lab HK tislelizumab-jsgr Zanidatamab-hrii Ziihera